BGI Genomics
Mei Liu is a seasoned professional currently serving as a Senior International Account Manager at BGI Genomics since August 2021, specializing in IVD technologies and multi-omics big data methods. Prior experience includes a role as Sales Manager at Shandong Haidike Medical Products Co., Ltd., where Mei Liu was responsible for international sales strategy and customer communication. Additional experience encompasses market research analysis at EF International Language Campuses and purchasing management at Turcoe GmbH, where a team was led in supplier relations and product quality assurance. Educational qualifications include a Bachelor's degree in English from Yan'an University and a language and marketing certificate from EF International Language Campuses in Manchester, UK.
This person is not in any offices
BGI Genomics
3 followers
BGI was founded in 1999 as a research organization to support the Human Genome Project. Over the years, BGI’s in-house research has contributed to the development of the field of Genomics in significant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. Today, BGI is actively participating in the fields of Cancer Research, Bio-sustainability and Personalized Medicine through a global network of collaborators. BGI Genomics is the world’s leading provider of genomic and proteomic services, now serving customers in more than 66 countries. We provide academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic and proteomic services and solutions across a broad range of applications spanning basic and translational research, drug discovery, agriculture and health care. To provide these services, we operate a large network of service Laboratories in China, Hong Kong, the US and Europe. Our customers benefit from the highest level of sequencing experience in the world to support their research and drug discovery projects. Our service laboratories operate under strict internationally recognized quality systems, such as those from CAP and ISO. More recently, BGI developed and launched its own DNBseq™ sequencing technology, based on DNA Nanoball sequencing technology that was invented in our Complete Genomics research facility in Silicon Valley, California. Scientists around the world now rely on DNBseq NGS services for the highest quality data at the lowest cost.